Professional Ginkgo Biloba Contract Manufacturer
KS Nutripharma is a ginkgo biloba supplement manufacturer and ginkgo extract manufacturer for OEM, ODM, and private-label programs. We qualify incoming leaf material as your ginkgo extract supplier on the finished project, then manufacture ginkgo leaf extract capsules, tablets, softgels, and powders—single-ingredient or combination—for cognitive and mental-health assortments, with a finalized grade, ginkgolic acid specification, and batch COA.
Ginkgo biloba supplement, ginkgo supplement, ginkgo leaf supplement, and ginkgo dietary supplement (including ginkgo food supplement on some briefs) name the same commercial category when the botanical is Ginkgo biloba L. leaf. Ginkgo supplements in this program use leaf extract or leaf powder. Seed is a separate material. Category assortments apply only when those actives are on the BOM. Powder, a named ratio, and a standardized ginkgo biloba extract are different purchase orders. Specify the raw material type, standardization profile, ginkgolic-acid limit if required, and milligrams per serving before you compare quotes.
24/6 is the most frequently requested commercial specification. Projects may also use customer-defined profiles (including 24/6, 24/5.5, or another named pair) depending on market and formulation requirements.
Already have a formula? Send Your BOM
Still choosing the grade? Request Formula Support
Comparing two quotes? Request a Sample / COA
Every incoming lot is verified against the approved raw-material specification before production. Depending on the project, incoming testing may include botanical identity, flavone glycosides, terpene lactones, ginkgolic acids (where specified), heavy metals, microbiological testing, and pesticides or PAH when the approved panel asks.
cGMP | ISO 9001 | ISO 22000 | HACCP | FSSC 22000 | Halal | Kosher | In-house lab + SGS/Eurofins pathways | Batch COA
→ About Us | Manufacturing Capacity | Certifications | Quality Control
12 production lines · 81,000+ m² · 260+ professionals · since 2007 · 500+ brands · 60+ markets
Ginkgo Biloba Supplement Manufacturing at a Glance
Items | Specifications |
|---|---|
| What we manufacture | Oral ginkgo leaf capsules, tablets, softgels, and powders. Liquids and gummies after feasibility |
| Botanical | Ginkgo biloba L. leaf |
| Extract type | Leaf powder · named ratio · standardized extract (24/6 is frequently requested; other named profiles on request) |
| Standardization | Flavone glycosides % + terpene lactones % + methods |
| Ginkgolic acids | Limit + method when the customer specification or market requirement asks |
| Frequently requested label | 60 / 120 / 240 mg extract per serving |
| Formulation options | F01–F07 starting formulas, customized per brief |
| Formats | Capsules first for a dry standardized extract. Tablets for pharmacy-compact. Softgels when the fill is oil. Powder / stick as its own specification |
| Documents | Batch COA; SGS/Eurofins when the RFQ requires it |
| MOQ / lead time | See MOQ, Samples and Lead Time |
Requirements on a ginkgo brief come from three places. Keep them named separately:
| Source | What it governs |
|---|---|
| Customer specification | The brand’s PO, panel, and COA fields |
| Market or regulatory requirement | Destination-market testing, claims, and warnings |
| Internal quality specification | KS release tests for the approved file |
Choose the Ginkgo Biloba Format: Capsules, Tablets, Softgels or Powder
Match milligrams, moisture, oil companions, and serving size after the formulation option is chosen. Most ginkgo leaf extract capsules start as hard capsules.
Note:
Liquids and gummies are project-scoped. The extract is bitter, brown-green, and dose-heavy for a pectin cook. Heat, piece assay, color, and flavor usually cost more than a capsule that already holds a commercial extract serving. Gummy ginkgo needs a dedicated pilot: extract load, flavor system, and piece assay agreed before commercial production.
Color, taste and appearance on the line
Color differences can occur when the assay still meets the specification. Taste, shade, and physical appearance still belong on the approved specification.
What buyers notice | What it usually means | Procurement note |
|---|---|---|
| Two lots look different | Residual composition, particle size, moisture | Re-assay if the specification requires it |
| Bitter or plant taste | Common for refined leaf extract | Identity still follows HPTLC / the named method |
| Capsule looks paler after packing | Light, moisture, translucent shell, lot color | Re-assay if the specification requires it |
| Sediment in a liquid | Solubility / suspension — liquids are project-scoped | Separate from capsule appearance |
| Speckles or mottling on tablets | Moisture, binder, or color migration | Hold and investigate |
Best for: F01, F03, F04, and F05 — when a ginkgo biloba capsules manufacturer path is the fastest start.
Why: Extract powders dose in the tens-to-low-hundreds of milligrams; a hard capsule holds the assay without a juice-style serving.
Typical formula cards: F01 · F03 · F04 · F05
What to finalize: Gelatin vs HPMC; extract mg; standardization profile; count per day; whether a second botanical shares the fill.
Manufacturing note: Default unit for a dry standardized powder.
→ Hard Capsules
Best for: F01 or F02 pharmacy-compact or high-count bottles.
Why: Cost and line speed when compression and color are acceptable.
Typical formula cards: F01 · F02
What to finalize: Extract or leaf mg; excipient load; film coat if color or dust is an issue; piece assay.
Manufacturing note: Tablet and capsule COAs are separate files. Mottling is a hold-and-investigate item — see appearance notes below.
→ Tablets
Best for: F06 when DHA or another oil shares the unit, or when the brief names an oil-type extract.
Why: Lipid fills and oxidation belong in a softgel or a second SKU.
Typical formula cards: F06
What to finalize: Die size; fill weight; gelatin vs vegan gel (starch/carrageenan — a vegan softgel is a plant-gel shell, distinct from an HPMC hard capsule); peroxide/anisidine if fish or algal oil is in; whether the dry extract is a second SKU.
Manufacturing note: HPMC is the vegetarian hard-capsule shell.
→ Softgel Solutions
Best for: F02 sticks and premixes, or extract-powder blends when the brand sells scoops.
Why: Leaf-powder servings are often larger than a single capsule.
Typical formula cards: F02
What to finalize: Leaf powder vs extract powder in the name; mg or g per stick; flavor and color; moisture; assay per stick if a standardized number will appear.
Manufacturing note: Leaf powder and standardized extract require different Supplement Facts declarations.
→ Powders and Granules
Custom Ginkgo Biloba Supplement Formulation for Private Label SKUs
Starting formulas for a finished ginkgo biloba dietary supplement, customized per brief. Pick the closest card or send a BOM. KS formulation team and R&D center match channel and market, then finalize the extract specification and ginkgolic acid fields against that BOM.
Note:
If the brief is a cognition line (several SKUs, not one ginkgo bottle), start from cognitive and mental-health supplements and treat ginkgo as one botanical you can specify.
Finished-product programs: supplement contract manufacturing.
Have a BOM? Send it · Still choosing? Get a Formula & Quote
Use when: The label will print a standardized ginkgo extract. The most frequently requested specification for a single-ingredient ginkgo supplement OEM SKU is 24/6; other named profiles are quoted when the customer specification says so.
Specify: Extract mg per serving; flavone % + terpene % + methods; acid limit if the customer or market file needs it; capsule vs tablet.
Main constraint: Only standardized extracts should be labeled with marker percentages. 24/6 describes a standardization profile rather than a proprietary extract brand. Finished-piece uniformity still belongs on the specification.
Use when: The bottle will print leaf-powder milligrams, or a named ratio, without a standardized-extract claim.
Specify: Plant part = leaf; powder vs ratio; mg as leaf or as extract; whether any flavonoid number will appear (if yes, you are closer to F01).
Main constraint: Extract study milligrams (often 120–240 mg) apply to standardized extract. Leaf powder and standardized extract require different milligram declarations. Bulk, color, and moisture differ from a refined extract.
Use when: The customer specification or a market requirement already names ginkgolic acids. Some customer files are tighter than the public low-ppm conversation.
Specify: ppm (or other unit) + method; whether the cap is a customer specification, a market/regulatory requirement, or both; incoming extract, finished product, or both.
Main constraint: Ginkgolic-acid limits and methods are written on the PO. A published ppm is a conversation number for that destination, and a tighter customer cap is not automatically a statutory limit.
Use when: The panel names both botanicals — the usual ginkgo ginseng supplement brief.
Specify: Each botanical identity; ginkgo mg + standardization; ginseng species + ginsenoside % + method; count per day.
Main constraint: A single blend weight does not identify the amount of each active. Quote a ginseng-led brief on the ginseng supplement manufacturer page.
Use when: Ginkgo is a supporting ingredient inside a memory-line SKU.
Specify: Ginkgo mg + standardization; Bacopa grade / bacosides if used; choline identity and mg.
Main constraint: Start product positioning from memory supplements. Attention-first briefs quote on focus supplements rather than stacking stimulants onto ginkgo.
Use when: Ginkgo sits next to phosphatidylserine and/or DHA.
Specify: Ginkgo mg + standardization; phosphatidylserine grade and mg; DHA source and mg; oil oxidation if softgel; soy vs sunflower PS if labeled.
Main constraint: Line brief → brain health supplements. Dual format (dry extract + oil DHA) when one unit cannot hold both honestly.
Use when: The BOM names a companion that is not F04–F06 — often lion’s mane and/or L-theanine.
Specify: Each identity and assay; fruiting-body vs mycelium if lion’s mane is labeled; serving size vs capsule count.
Main constraint: Formulations are developed from the approved BOM, target market, and specification rather than generic retail formulas.
Extract type is usually finalized before quotation because powder, ratio extracts, and standardized extracts are different specifications. Use this table, then pick F01–F07 or send a BOM.
| If your brand… | Usually starts with |
|---|---|
| Wants a numbered standardized ginkgo extract on the panel | F01 — 24/6 is frequently requested; usually a private label ginkgo capsule |
| Customer or import QA already names ginkgolic acids | F03 — same chemistry plus a stated acid limit |
| Will print leaf-powder milligrams, not flavonoid percentages | F02 — powder or a named ratio only |
| Needs a vegetarian capsule | F01 or F03 in HPMC |
| Already sells ginkgo with ginseng as one pair | F04 — two identities, two assays |
| Wants ginkgo as a supporting ingredient next to Bacopa or a choline donor | F05 |
| Wants ginkgo next to phosphatidylserine or DHA | F06 — capsule or softgel depending on the lipid |
| Names another companion (lion’s mane, L-theanine, or a listed BOM) | F07 |
Decision path: Need a standardized number on the label? No → F02. Yes → F01 (or another named profile). Acid limit required by the customer or the market? → F03. Oil or DHA in the same unit? → softgel (often F06). Dry extract only? → hard capsule first.
A usable PO names plant part, extract type, and standardization profile — then ginkgolic acids if the customer specification or market requirement includes them. “Ginkgo 120 mg” without those fields is incomplete. See standard extracts.
| Extract type | What the label can honestly say | Commercial use | Specification rule |
|---|---|---|---|
| Leaf powder (F02) | Ginkgo leaf powder, mg as leaf | Identity, economy, stick packs | Leaf powder and standardized extract require different milligram declarations |
| Ratio extract (F02) | A named ratio only if the file uses a real ratio | Extract without a standardized claim | Ratio claims should match the manufacturing specification |
| Standardized extract (F01 / F03) | Flavone glycosides and terpene lactones %, methods named | 24/6 is frequently requested; other named pairs when specified | 24/6 describes a standardization profile rather than a proprietary extract brand |
24/6 means about 24% flavone glycosides and about 6% terpene lactones (ginkgolides and bilobalide). Flavone glycosides are often calculated from hydrolyzed aglycones (quercetin, kaempferol, and isorhamnetin) — the method on the PO has to match the COA. Two factories can print the same percentages and still not have made the same extract.
Ginkgolic acids are alkylphenols controlled on many refined extracts. Public pharmacopoeial and industry references discuss low-ppm limits for refined dry extracts. The applicable number depends on the destination market and the customer specification — write the cap and the method on the PO.
Example specification
Example specification for discussion only.
| Parameter | Example |
|---|---|
| Botanical | Ginkgo biloba L. leaf |
| Extract type | Standardized dry extract |
| Standardization profile | Flavone glycosides ~24% / terpene lactones ~6%, methods named |
| Appearance | Brown-yellow to brown-green powder |
| Assay | HPLC as agreed on the approved specification |
| Ginkgolic acids | As customer specification and/or market requirement |
| Heavy metals, micro, pesticides, PAH | According to the approved specification |
Why two standardized extracts can quote different prices
A cheaper line with the same printed percentages is a different purchase until extract type, solvent and purification, the ginkgolic acid field (silent vs stated), assay methods, origin and lot consistency, and documentation depth (identity, metals, micro, pesticides, PAH) match. 24/6 describes a standardization profile rather than a proprietary extract brand.
Finalize before sampling: species + leaf · powder vs ratio vs standardized profile · flavone % + method · terpene % + method · ginkgolic acids if required · mg basis · incoming vs finished assay.
Align these points before you rank two ginkgo leaf extract quotations. Send both specifications or COAs with the RFQ.
| Ask | Why it changes the number |
|---|---|
| Same plant part? | Leaf and seed are different materials |
| Same extract type? | Powder, ratio, and standardized extract are different specifications |
| Same profile and methods? | “Standardized” without flavone % + terpene % + methods is incomplete |
| Same ginkgolic acid field? | Silent vs stated ppm is a different refining file |
| Same milligram basis? | Extract mg and leaf-powder mg are different declarations |
| Same finished testing? | A drum COA covers the incoming extract; the bottle still needs a finished-product COA |
| Same pack, MOQ, and lead time? | Format and pack change the commercial number |
Procurement checklist: plant part · extract type · marker assay · method · ginkgolic acids if required · origin if required · COA scope · shelf-life basis · packaging · MOQ · lead time.
Freeze labeled milligrams and the basis (extract vs leaf) before comparing quotes. A higher milligram figure is a different brief, not automatically a stronger product.
Frequently requested labels for standardized leaf extracts use 60, 120, or 240 mg extract per serving. Public research on named preparations is often discussed in the 120–240 mg/day extract range for those products. Those figures are development context; they do not transfer to a leaf-powder stick.
| Frequently requested label | Industry practice |
|---|---|
| 60 mg extract | Common unit dose; older bottles often used two units |
| 120 mg extract | Common once-daily panel |
| 240 mg extract | Upper commercial / research-adjacent talk for named extracts |
| Leaf-powder hundreds of mg | F02 identity fill; different milligram basis from 120 mg of a 24/6 extract |
| Named-extract study range | Context for those preparations |
Label extract mg × (flavone % or terpene %) equals marker mg when the method and basis match the COA. Fresh-leaf equivalent claims belong only when the manufacturing specification defines the conversion. Combination formulas name every active in milligrams. Overage follows stability data.
Each companion needs its own identity and assay.
| Companion | Where it usually sits | What to finalize |
|---|---|---|
| Ginseng | F04 | Species + ginsenosides + method |
| Bacopa / choline donor | F05 | Bacosides or choline identity + mg |
| Phosphatidylserine / DHA | F06 | Grade, source, oil oxidation if softgel |
| Lion’s mane / L-theanine | F07 | Fruiting-body vs mycelium if labeled; theanine mg |
| Vitamin B complex or magnesium | Custom BOM | Each assay; capsule count vs serving |
| Green tea or caffeine | Rarely a default | Extra label review — a stimulant on the BOM is a different specification from a non-stimulant ginkgo brief |
A single blend weight does not identify the amount of each active. Send the BOM if the companion is not on F04–F07.
A development checklist for leaf identity, extract type, methods, and finished COA.
| Evaluation point | What to check |
|---|---|
| Identity | Ginkgo biloba leaf |
| Extract type | Powder, ratio, or standardized profile, named on the PO |
| Methods | Flavone and terpene assays that match the COA |
| Ginkgolic acids | Limit + method when the customer or market file asks |
| Finished assay | Drum COA vs the unit you will sell |
| Label and documents | Permitted structure/function wording; batch COA on the approved panel |
See How to Compare Two Quotes and Common Mistakes.
- Ranking two standardized-extract prices without methods, acid limits, or milligram basis.
- Treating a raw-material COA as the finished bottle.
- Copying extract study milligrams onto a leaf-powder fill.
- Leaving ginkgolic acids silent when the customer or market file will ask.
- One blend weight for ginkgo plus ginseng, Bacopa, or PS.
- Putting a dry extract and fish or algal oil in one dishonest fill.
- Assuming gummies are a catalog default.
- Printing another company’s clinical extract brand name as the house 24/6.
A finished ginkgo product is usually sold as a botanical in a cognitive-wellness assortment, or as a supporting ingredient on an F05 / F06 BOM. Structure/function wording must follow destination-market regulations.
Disease claims such as dementia, tinnitus, or hearing-loss treatment are not permitted on dietary supplement labels in most markets. Research on named standardized leaf extracts does not transfer disease language onto a leaf-powder capsule.
United States: dietary-supplement structure/function rules. European Union: authorized health-claim lists. An OTC dietary-supplement path and a prescription drug path are separate files.
This section supports finished-label review.
Possible complaints include gastrointestinal discomfort and headache. Sensitivity or rash belongs on the warning set when the destination market requires it. Incidence varies by formulation and published evidence, so warning language is developed according to destination-market requirements.
Concurrent anticoagulant or antiplatelet use and planned surgery are destination-market warning files. Pre-surgery discontinuation advice belongs to healthcare providers and local clinical guidance rather than product specifications.
Pregnancy or lactation is not a default SKU. Infant products are not manufactured here. Tinnitus and cognitive-decline briefs are clinical-path items. Seed and leaf extract are different toxicology files. F04 ginseng adds a second interaction review; F06 lipids add oxidation control.
Raw-material qualification workflow
Supplier qualification → raw-material COA review → identity confirmation → incoming QC → production release → finished-product testing → QA approval and batch COA.
Results outside the agreed specification go on hold for investigation. The batch is released only after the deviation is closed under a documented QA procedure.
Incoming panel (as scoped): botanical identity (Ginkgo biloba leaf); flavone glycosides; terpene lactones; ginkgolic acids where specified; micro; heavy metals; pesticides and PAH when the approved panel asks.
In-process: blend uniformity; fill or tablet weight.
Finished: agreed identity and potency; acids if in the finished specification; micro; pack.
In-house lab plus SGS/Eurofins when the RFQ requires a third-party report. Quality control.
Finished-product COA includes
| Block | Examples |
|---|---|
| Identification | Species + leaf; extract type as specified |
| Assay | Flavones and/or terpenes as agreed; piece or stick assay |
| Uniformity | Blend / fill / tablet weight as scoped |
| Microbiology / heavy metals | Limits on the approved specification |
| Ginkgolic acids | When the finished specification includes them |
| Moisture / appearance / net content | Physical release |
| Packaging verification | Pack vs approved artwork and count |
A sample COA is issued against the approved specification — request one.
Origin, lot consistency, and stability
Name origin on the PO when the brief requires it. China and Europe appear often in market practice; lot-to-lot consistency and supplier qualification matter more than a country name on the spec sheet.
Refined standardized powders are moisture-sensitive. Keep induction seals and desiccant in scope when needed. Oil fills add light and oxygen control. Dating comes from formulation, pack, storage, and stability data.
Pack starts with moisture and, for oil fills, oxygen and light — then dosage form, count, and shipping.
HDPE or PET bottles with induction sealing are a common start for capsules and tablets. Softgels need a dry pack after encapsulation. Powder and stick SKUs need moisture and color control.
Supplement Facts must match leaf, extract type, and milligram basis on the COA. If the panel prints a standardization profile, the methods have to point back to the specification. Anticoagulant warning language follows the destination market. Bottle counts are often 30, 60, 90, or 120.
01. RFQ — Market, formulation option or BOM, extract type, milligrams, format, pack, claim constraints.
02. Feasibility — Standardization, acids, companions, fill.
03. Sample — Against the approved specification.
04. Approval — Assay, appearance, pack.
05. Artwork — Supplement Facts versus named lines and warnings.
06. Production — Commercial batch.
07. QA release — Incoming, in-process, finished, hold/release.
08. Shipment — Export documents and dispatch.
Planning quantities. Final MOQ depends on formula, packaging, and production setup.
Stage | Planning range |
|---|---|
| Sample | 7–15 days after the specification is approved |
| Pilot | 15–25 days |
| Mass production | 30–45 days after approval and scheduling |
| Stability (when scoped) | Set per pack and formula |
Scope | Starting range |
|---|---|
| Capsules | ~3,000–5,000 units |
| Tablets | ~5,000–10,000 units |
| Softgels | ~3,000–5,000 units |
| Powder / stick | Often from ~10,000 units |
| Liquid / gummies | Project-scoped |
| Bulk on the finished project | Quoted by kg |
Dual-assay combos, oil-fill oxidation, and a tight acid field add time before the sample clock. Ginkgo extract bulk on a finished-product project is quoted by kilogram against the same specification as the bottle.
Why Source Ginkgo Ingredients and Finished Supplements From KS Nutripharma?
One specification from leaf identity through the finished extract and the ginkgolic acid field — then the same team runs formulation, dosage form, pack, and batch release. F01–F07 are starting formulas, customized per brief.
5 bases · 81,000+ m² · 12 production lines · 260+ professionals · since 2007 · 500+ brands · 60+ markets
Get a Usable Ginkgo Biloba Supplement Quote
- Destination market
- F01–F07 or BOM
- Leaf + extract type (powder, ratio, or standardized) + mg basis
- Flavone % + terpene % + methods; ginkgolic-acid limit if required
- Format and pack
- Quantity, timeline, and permitted structure/function wording (plus anticoagulant warning if in scope)
- Existing CoA
Send Your BOM · Request Formula Support
A finished oral dietary supplement from Ginkgo biloba leaf. Ginkgo supplement, ginkgo leaf supplement, and ginkgo dietary supplement name the same commercial category when the botanical is leaf.
Ginkgo and ginkgo biloba name the same leaf category. Ginko and gingko are misspellings of that name.
See What Makes a Good. Compare leaf identity, extract type, methods, the acid field, and finished COA.
About 24% flavone glycosides and 6% terpene lactones, methods named. 24/6 describes a standardization profile. Other named pairs are quoted when the customer specification says so. See Extract Specs.
Leaf powder and standardized extract require different Supplement Facts declarations. Treat the change as a new specification.
Yes, after qualification against the approved specification. A finished-product COA is still issued on the unit you will sell.
The incoming COA is reviewed. A finished-product COA is still written to the approved file. Import and customer requirements differ, so one report rarely covers every market panel.
Map methods before you compare quotes. Hydrolysis calculations and split terpene reports need a method bridge.
Set per formula and pack. Dating comes from that data. Sample lead time (7–15 days after spec lock) is a sample clock, separate from a stability study.
See Color, taste and appearance. Shade and bitterness can differ when the assay still meets the specification.
Those briefs are clinical-path items. Dietary-supplement programs use destination-market structure/function wording.
